Background-Elevation of baseline cardiac troponin in patients presenting with acute coronary syndromes (ACS) confers an adverse prognosis. The prognostic value of troponin elevation in patients with chronic kidney disease (CKD) and ACS is less certain.

The curves in Figure 2 of the above-mentioned article were missing. The error is regretted. The corrected figures are reproduced below. Figure 2. Kaplan-Meier curves representing the estimated incidence of death (A), death or myocardial infarction (B), stent thrombosis (C), target vessel revascularization (D), and major adverse cardiac events (E) in patients who received drug-eluting stents and those who received bare metal stents. The median duration of follow-up for each of the study end-points was as follows: death 866 days, death or MI 606 days, stent thrombosis 583 days, TVR 422 days, MACE 450 days. Numbers of patients at risk in each of the study groups are shown at various follow-up durations. The Y-axis represents the proportion of patients who suffered the clinical outcome. For each study end-point, 1-year outcomes in the DES and BMS groups are shown.

No abstract

No abstract